Management of steroid-resistant focal segmental glomerulosclerosis in children using tacrolimus

American Journal of Nephrology

Volumn 26, Issue 6, 2007, Pages 544-551

  Bhimma, Rajendra ^a   Adhikari, Miriam ^a   Asharam, Kareshma ^a   Connolly, Catherine ^a  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

Author keywords

Children, steroid resistance; Nephrotic syndrome; Steroid resistant FSGS, children; Steroid resistant FSGS, management; Tacrolimus treatment in children

Indexed keywords

ANTILIPEMIC AGENT; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOLIC ACID; METHYLPREDNISOLONE; MULTIVITAMIN; STEROID; TACROLIMUS;

ADOLESCENT; AGE DISTRIBUTION; ANEMIA; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DEATH; DIALYSIS; DIARRHEA; DISEASE DURATION; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FOCAL GLOMERULOSCLEROSIS; FOCAL SEGMENTAL GLOMERULOSCLEROSIS; FOLLOW UP; HUMAN; HUMAN TISSUE; HYPERTENSION; LOW DRUG DOSE; MALE; NAUSEA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RELAPSE; REMISSION; SEPSIS; TREATMENT OUTCOME;

ADOLESCENT; CHILD; FEMALE; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; STEROIDS; TACROLIMUS; TREATMENT OUTCOME;

EID: 33846414692     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000097864     Document Type: Article

References (47)

1. Baqi N, Singh A, Balachandra A, Ahmed H, Nicastri A, Kytinski S, Homel P, Tejani A: The paucity of minimal change disease in adolescents with primary nephrotic syndrome. Pediatr Nephrol 1998;12:105-107.
2. Ichikawa I, Fogo A: Focal segmental glomerulosclerosis. Pediatr Nephrol 1996;10:374-391.
3. Srivastava T, Simon S, Alon U: High incidence of focal segmental glomerulosclerosis in nephrotic syndrome in childhood. Pediatr Nephrol 1999;13:13-18.
4. Cameron JS, Turner DR, Ogg CS, Chantler C, Williams DG: The long-term prognosis of patients with focal segmental glomerulosclerosis. Clin Nephrol 1978;10:213-218.
5. Korbet SM, Schwartz MM, Lewis EG: Primary focal segmental glomerulosclerosis: clinical course and response to therapy. Am J Kidney Dis 1994;23:773-783.
6. Rydell JJ, Korbet SM, Borok RZ, Schwartz MM: Focal glomerular sclerosis in adults: presentation, course and response to treatment. Am J Kidney Dis 1995;25:534-542.
7. Mendoza SA, Reznik VM, Grisworld WR, Krensky AM, Yorgin PD, Tune BM: Treatment of steroid-resistant focal segmental glomerulosclerosis with pulse methylprednisolone and alkylating agents. Pediatr Nephrol 1990;4:303-307.
8. Tune BM, Lieberman E, Mendoza SA: Steroid-resistant nephrotic focal segmental glomerulosclerosis: a treatable disease. Pediatr Nephrol 1996;10:772-778.
9. Yorgin PD, Krasher J, Al-Urzi AY: Pulse methylprednisolone treatment of idiopathic steroid-resistant nephrotic syndrome. Pediatr Nephrol 2001;16:245-250.
10. Hari P, Bagga A, Jinda N, Srivastava RN: Treatment of focal glomerulosclerosis with pulse steroids and oral cyclophosphamide. Pediatr Nephrol 2001;16:901-905.
11. Vester U, Kranz B, Zimmermann S, Hoyer PF: Cyclophosphamide in steroid-sensitive nephrotic syndrome: outcome and outlook. Pediatr Nephrol 2003;18:661-664.
12. Chandra M, Susin M, Abitbol C: Remission of relapsing childhood nephrotic syndrome with mycophenolate mofetil. Pediatr Nephrol 2000;14:224-226.
13. Mendizabal S, Zamora I, Berbel O, Sanahuja MJ, Fuentes J, Simon J: Mycophenolate mofetil in steroid/cyclosporine-dependent/resistant nephrotic syndrome 2005;20:914-919.
14. Inoue Y, Lijima K, Nakamura H, Yoshikawa N: Two year cyclosporine treatment in children with steroid-dependent nephrotic syndrome. Pediatr Nephrol 1999;13:33-38.
15. Singh A, Tejani C, Tejani A: One-centre experience with cyclosporine in refractory nephrotic syndrome in children. Pediatr Nephrol 1999;13:26-32.
16. Barletta GM, Smoyer WE, Bunchman TE, Flynn JT, Kershaw DB: Use of mycophenolate mofetil in steroid-dependent and resistant nephrotic syndrome. Pediatr Nephrol 2003;18:833-837.
17. Lijima K, Hamahira K, Tanaka R, Kobayashi A, Nozu K, Nakamura H, Yoshikawa N: Risk factors for cyclosporine-induced tubulointerstitial lesions in children with minimal change nephrotic syndrome. Kidney Int 2002;61:1801-1805.
18. Jordan ML, Shapiro R, Vivas CA, Scantlebury VP, Rhandhawa P, Carrieri G, McGauley J, Dermetris AJ, Tzakis A, Fung JJ, et al: FK-506 'rescue' for resistance rejection of renal allografts under primary cyclosporine immunosuppression. Transplantation 1994;57:860-865.
19. European FK-506 Multicentre Liver Study Group: Randomized trial comparing tacrolimus (FK-506) and cyclosporin in prevention of liver allograft rejection. Lancet 1994;344:423-428.
20. Denton MD, Magee CC, Sayegh MH: Immunosuppressive strategies in transplantation. Lancet 1999;353:1083-1091.
21. Schweda F, Liebl R, Riegger GAJ, Kramer BK: Tacrolimus treatment for steroid-and cyclosporin-resistant minimal-change nephrotic syndrome. Nephrol Dial Transplant 1997;12:2433-2435.
22. Segarra A, Vila J, Pou L, Majo J, Arbos A, Quiles T, Piera L: Combined therapy of tacrolimus and corticosteroids in cyclosporin-resistant or -dependent idiopathic focal glomerulosclerosis: a preliminary uncontrolled study with prospective follow-up. Nephrol Dial Transplant 2002;17:655-662.
23. Pennesi M, Gagliardo A, Minisini S: Effective tacrolimus treatment in a child suffering from severe nephrotic syndrome. Pediatr Nephrol 2003;18:477-478.
24. Loeffler K, Gowrishanker M, Yiu V: Tacrolimus therapy in pediatric patients with treatment-resistant nephrotic syndrome. Pediatr Nephrol 2004;19:281-287.
25. McCauley J, Tzakis AG, Fung JJ, Todo S, Starzl TE: FK-506 in steroid-resistant focal sclerosing glomerulonephritis of childhood. Lancet 1990;335:674.
26. McCauley J, Shapiro R, Ellis D, Igdal H, Tzakis A, Starzl TE: Pilot trial of FK-506 in the management of steroid-resistant nephrotic syndrome. Nephrol Dial Transplant 1993;8:1286-1290.
27. Kramer BK, Schweda F: Differing proteinuria control with cyclosporin and tacrolimus. Lancet 1997;349:953-954.
28. Wang SC, Zeevi A, Jordanml, Simmons RL, Tweardy DJ: FK-506, rapamycin, and cyclosporine: effects on IL-10 mRNA levels in a T-helper 2 cell line. Transplant Proc 1991;23:2920-2922.
29. Wang T, Donahoe PK, Zervos AS: Specific interaction of type I receptors of the TGF-β family with the immunophilin FKBP-12. Science 1994;265:674-676.
30. Bishop DK, Li W: Cyclosporin A and FK-506 mediate differential effects on T cell activation in vivo. J Immunol 1992;148:1049-1054.
31. Franz S, Faul C, Mundel PJ: Cyclosporin protects podocyte stress fibers through stabilization of synaptopodin protein expression. J Am Soc Nephrol 2005;16:109, abstr SA-FC123.
32. Consensus Statement on Management and Audit Potential for Steroid-Responsive Nephrotic Syndrome: Report of a Workshop by the British Association for Paediatric Nephrology and Research Unit, Royal College of Physicians. Arch Dis Child 1994;70:151-157.
33. Pesce MA, Strande CS: A new micro method for determination of protein in cerebrospinal fluid and urine. Clin Chem 1973;19:1265-1267.
34. K/DOQ1 Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, classification, and stratification. Am J Dis Feb 2002;39(suppl 1):S1-S266.
35. Anonymous: Update on the 1987 Task Force Report on High-Blood Pressure in Children and Adolescents: A working group report from the National High Blood Pressure Education Program. Pediatrics 1996;98:649-658.
36. Schwartz GJ, Haycock GB, Edelman CM, Spitzer A: A simple estimation of glomerular filtration rate in children derived from body weight and plasma creatinine. Pediatrics 1967;58:259-263.
37. Niaudet P: French Society of Pediatric Nephrology. Comparison of cyclosporine and chlorambucil in the treatment of steroid-dependent idiopathic nephrotic syndrome: a multicentre randomized controlled trial. Pediatr Nephrol 1992;6:1-3.
38. Niaudet P, Habib R: Cyclosporine in the treatment of idiopathic nephrosis. J Am Soc Nephrol 1994;5:1049-1056.
39. Tejani A, Suthanthiran M, Pomerantz A: A randomized controlled trial of low-dose prednisone and cyclosporine versus high-dose prednisone in nephrotic syndrome in children. Nephron 1991;59:96-99.
40. Ponticelli C, Edefonti A, Ghio L, Rizzoni G, Rinaldi S, Gusmano R, Lama G, Zacchello G, Confalonieri R, Altieri P, et al: Cyclosporin versus cyclophosphamide for patients with steroid-dependent and frequently relapsing idiopathic nephrotic syndrome: a multicentre randomized controlled trial. Nephrol Dial Transplant 1993;8:1326-1332.
41. Ponticelli C, Rizzoni G, Edefonti A, Altieri P, Rivolta E, Rinaldi S, Ghio L, Lusvarghi E, Gusmano R, Locatelli F, et al: A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome. Kidney Int 1993;43:1377-1384.
42. Meyrier A: Treatment of idiopathic nephrosis by immunophillin modulation Nephrol Dial Transplant 2003;18(suppl 6):vi79-vi86.
43. Cattran DC, Appel GB, Hebert LA, Hunsicker LG, Pohl MA, Hoy WE, Maxwell DR, Kunis CL: A randomised trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group. Kidney Int 1999;56:2220-2226.
44. Budde K, Fritsche L, Neumayer HH: Differing proteinuria control with cyclosporine and tacrolimus. Lancet 1997;349:330.
45. Kessler M, Champigneulles J, Hestin D, Frimat L, Renoult E: A renal allograft recipient with late recurrence of focal and segmental glomerulosclerosis after switching from cyclosporine to tacrolimus. Transplantation 1999;67:641-643.
46. Maruyama K, Tomizawa S, Sekei Y, Arai H, Kuroume T: Inhibition of vascular permeability factor production by cyclosporine in minimal change nephrotic syndrome. Nephron 1992;62:27-30.
47. Maruyama K, Tamizawa S, Sekei Y, Arai J, Ogawa T, Kuroume T: FK-506 for vascular permeability factor production in minimal change nephrotic syndrome. Nephron 1994;66:486-487.